Risk factors for persistent positive anticardiolipin antibodies in women with recurrent pregnancy loss

被引:4
作者
Yokote, R. [1 ]
Kuwabara, Y. [1 ,2 ]
Kasano, S. [1 ]
Yonezawa, M. [1 ]
Ouchi, N. [1 ]
Ichikawa, T. [1 ]
Suzuki, S. [1 ]
Takeshita, T. [1 ]
机构
[1] Nippon Med Sch, Dept Obstet & Gynecol, 1-1-5 Sendagi,Bunkyo Ku, Tokyo 1138603, Japan
[2] 1-1-5 Sendagi,Bunkyo Ku, Tokyo 1138603, Japan
基金
日本学术振兴会;
关键词
Antiphospholipid syndrome; Recurrent pregnancy loss; Anticardiolipin antibody; FACTOR-XII; ANTIPHOSPHATIDYLETHANOLAMINE ANTIBODIES; CLASSIFICATION; CRITERIA;
D O I
10.1016/j.jri.2023.103920
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Antiphospholipid syndrome (APS) is an established cause of recurrent pregnancy loss (RPL). It is necessary to detect persistently positive antiphospholipid antibodies to diagnose APS. This study aimed to explore risk factors for persistent anticardiolipin (aCL) positivity. Women with a history of RPL or with a history of one or more intrauterine fetal deaths after 10 weeks underwent examinations to determine the causes of RPL, including antiphospholipid antibodies. If aCL-IgG or aCL-IgM antibodies were positive, retests were performed at least 12 weeks apart. Risk factors for persistent aCL antibody positivity were retrospectively investigated. The number and percentage of cases above the 99th percentile were 74/2399 (3.1%) for aCL-IgG, and 81/2399 (3.5%) for aCL-IgM. Of the initially tested cases, 2.3% (56/2399) for aCL-IgG and 2.0% (46/2289) for aCL-IgM were ulti-mately positive above the 99th percentile in retests. Retest values after 12 weeks were significantly lower than the initial values for both IgG and IgM immunoglobulin classes. Initial aCL antibody titers were significantly higher in the persistent-positive group than in the transient-positive group for both IgG and IgM immunoglobulin classes. The cut-off values for predicting persistent positivity of aCL-IgG antibodies and aCL-IgM antibodies were 15 U/mL (99.1 percentile) and 11 U/mL (99.2 percentile), respectively. The only risk factor for persistently positive aCL antibodies is a high antibody titer during the initial test. When the aCL antibody titer in the initial test exceeds the cut-off value, therapeutic strategies can be defined in subsequent pregnancies without waiting for 12 weeks.
引用
收藏
页数:6
相关论文
共 23 条
  • [1] Systematic review of case reports of antiphospholipid syndrome following infection
    Abdel-Wahab, N.
    Lopez-Olivo, M. A.
    Pinto-Patarroyo, G. P.
    Suarez-Almazor, M. E.
    [J]. LUPUS, 2016, 25 (14) : 1520 - 1531
  • [3] Extended persistence of antiphospholipid antibodies beyond the 12-week time interval: Association with baseline antiphospholipid antibodies titres
    Devignes, Jean
    Smail-Tabbone, Malika
    Herve, Alex
    Cagninacci, Geoffroy
    Devignes, Marie-Dominique
    Lecompte, Thomas
    Zuily, Stephane
    Wahl, Denis
    [J]. INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY, 2019, 41 (06) : 726 - 730
  • [4] Antiphospholipid antibodies in patients with COVID-19: A relevant observation?
    Devreese, Katrien M. J.
    Linskens, Eleni A.
    Benoit, Dominique
    Peperstraete, Harlinde
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2020, 18 (09) : 2191 - 2201
  • [5] El Hachem H, 2017, INT J WOMENS HEALTH, V9, P331, DOI 10.2147/IJWH.S100817
  • [6] COVID-19 and Antiphospholipid Antibodies: Time for a Reality Check?
    Favaloro, Emmanuel J.
    Henry, Brandon Michael
    Lippi, Giuseppe
    [J]. SEMINARS IN THROMBOSIS AND HEMOSTASIS, 2022, 48 (01) : 72 - 92
  • [7] HARRIS EN, 1987, CLIN EXP IMMUNOL, V68, P215
  • [8] Jones DW, 1999, THROMB HAEMOSTASIS, V81, P387
  • [9] International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)
    Miyakis, S
    Lockshin, MD
    Atsumi, T
    Branch, DW
    Brey, RL
    Cervera, R
    Derksen, RHWM
    De Groot, PG
    Koike, T
    Meroni, PL
    Reber, G
    Shoenfeld, Y
    Tincani, A
    Vlachoyiannopoulos, PG
    Krilis, SA
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2006, 4 (02) : 295 - 306
  • [10] Clinical Application of Revised Laboratory Classification Criteria for Antiphospholipid Antibody Syndrome: Is the Follow-Up Interval of 12 Weeks Instead of 6 Weeks Significantly Useful?
    Park, Sang Hyuk
    Jang, Seongsoo
    Park, Chan-Jeoung
    Chi, Hyun-Sook
    [J]. BIOMED RESEARCH INTERNATIONAL, 2016, 2016